Speaker Profile

Ph.D., RAC, Vice President Translational Medicine & Companion Diagnostics, Mirati Therapeutics

Dr. Anderes has worked in a variety of roles that were initially the precursors to today’s Precision Medicine including a number of senior executive/scientific advisory positions at pharmaceutical, biotech and medical device companies. Dr. Anderes acquired very broad, interdisciplinary technical, regulatory and business skills, with an extensive knowledgebase in clinical research, and vitro diagnostic device development. Achievements range from lead identification of new molecular entities to characterization of clinical development candidates for several distinct first in class molecular targeted agents to treat cancer. In parallel to drug discovery/development activities, Dr. Anderes has lead equally diverse biomarker and companion diagnostic projects from biological validation to clinical trial assay development to regulatory approval roadmaps across multiple platform technologies. She has been involved in the development of state of the art liquid biopsy approaches to evaluate clinical utility of CTCs and ctDNA.

 Session Abstract – PMWC 2022 Silicon Valley

Alzheimer’s disease is one of our nation’s most significant threats, with devastating impacts on patients and their families. This session will explore a new approach called neurodiagnostic therapies, a methodology fundamentally enabled by ultrasensitive biomarker measurements that allow visibility to neurological disease in individuals before they are symptomatic. This allows treatment to be administered at a more optimal stage, to improve therapeutic effectiveness and by extension, patient outcomes.

During this presentation, attendees will learn how this new approach can provide early treatment to ultimately accelerate disease detection and improve outcomes, in addition to creating viable and credible evidence for the healthcare system to adopt it with coverage to facilitate frictionless access.